Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

Inclusion Criteria: * Active psoriatic nail disease defined as a Minimum 4 or more fingernails OR NAPSI\>20 * Active skin psoriasis currently (no minimum PASI or BSA) or skin psoriasis in the past documented by a dermatologist * Age 18-85 Exclusion Criteria: * History of IL-17 inhibitor use (other therapies including TNF inhibitors or non- biologics DMARDS in the past are acceptable) * Inflammatory bowel disease * Metal implants or other concerns for use of MRI * Active infection * Patients may have a history of self-reported psoriatic arthritis but may not have active PsA at the time of screening. * We will exclude patients with onychomyosis of the fingernails on clippings